Care net profit up 32% to SAR 99.6 mln in 9M 2021

National Medical Care Co. (Care) reported a net profit after Zakat and tax of SAR 99.6 million for the first nine months of 2021, a 32% increase from SAR 75.3 million in the year-earlier period.

The profit rise was attributed to increased volume of business with the General Organization for Social Insurance (GOSI), cash patients and direct contracts.

The company also cited better profit margins due to rationalization of general expenses and a decline in the cost of sales-to-revenue ratio.

Lower operating expenses (OPEX) also boosted the nine-month profit.

Financials (M)

Item	9m 2020	9m 2021	Change‬
Revenues	594.36	629.79	6.0 %
Gross Income	162.15	184.49	13.8 %
Operating Income	88.75	119.57	34.7 %
Net Income	75.27	99.64	32.4 %
Average Shares	44.85	44.85	-
EPS (Riyals)	1.68	2.22	32.4 %

In Q3 2021, net profit after Zakat and tax more than doubled to SAR 33.2 million from SAR 16.3 million a year earlier, driven by lower cost of sales, compared to the current quarter revenue, which in turn increased gross profit margins to 30% from 24% in Q3 2020. Care also cited a decline in OPEX.

When compared to the previous quarter, Q3 net profit grew by 8% from SAR 30.7 million on a 5% rise in revenue and higher gross profit margins.

Current Quarter Comparison (M)

Compared With The

Item	Q3 2020	Q3 2021	Change‬
Revenues	213.31	213.11	(0.1 %)
Gross Income	51.06	63.08	23.5 %
Operating Income	22.70	39.80	75.3 %
Net Income	16.32	33.17	103.2 %
Average Shares	44.85	44.85	-
EPS (Riyals)	0.36	0.74	103.2 %

Item	Q2 2021	Q3 2021	Change‬
Revenues	202.49	213.11	5.2 %
Gross Income	57.77	63.08	9.2 %
Operating Income	37.59	39.80	5.9 %
Net Income	30.74	33.17	7.9 %
Average Shares	44.85	44.85	-
EPS (Riyals)	0.69	0.74	7.9 %

Shareholders’ equity, after minority interest, grew by 7% to SAR 1.091 billion as of Sept. 30, 2021, from SAR 1.018 billion a year earlier.

View more financial results

View other reports

Share Price

National Medical Care Co. (CARE)

	Current
Market Cap (M Riyal)	7,274.67
Enterprise Value (EV) (M)	7,259.16
Shares Outstanding ((M))	44.85
EPS ( Riyal) (TTM)	6.12
Book Value (BV) ( Riyal)	34.35
Par Value ( Riyal)	10.00
Adjusted P/E (Last12)	29.64
P/E (TTM)	26.51
Price/book	4.72
Return on Average Assets (%) (TTM)	13.3
Return on Average Equity (%) (TTM)	18.7

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
Q1 2012	128.87	13.0 %	35.53	3.2 %	28.74	(0.2 %)
Q2 2012	137.27	15.1 %	37.60	9.2 %	30.40	9.5 %
Q3 2012	121.00	13.6 %	30.07	23.9 %	21.63	17.4 %
Q4 2012	137.61	16.2 %	31.93	13.3 %	23.24	15.1 %
2012	524.75	14.5 %	135.13	11.4 %	104.01	9.3 %
Q1 2013	145.36	12.8 %	38.75	9.0 %	31.05	8.0 %
Q2 2013	142.20	3.6 %	31.78	(15.5 %)	21.64	(28.8 %)
Q3 2013	134.56	11.2 %	24.08	(19.9 %)	17.45	(19.3 %)
Q4 2013	164.16	19.3 %	33.54	5.0 %	21.42	(7.8 %)
2013	586.28	11.7 %	130.06	(3.8 %)	91.55	(12.0 %)
Q1 2014	181.82	25.1 %	42.99	10.9 %	31.12	0.2 %
Q2 2014	179.74	26.4 %	56.27	77.0 %	29.95	38.4 %
Q3 2014	177.44	31.9 %	40.16	66.8 %	18.41	5.5 %
Q4 2014	194.99	18.8 %	37.85	12.9 %	12.23	(42.9 %)
2014	733.99	25.2 %	177.27	36.3 %	92.67	1.2 %
Q1 2015	219.43	20.7 %	54.12	25.9 %	29.12	(6.4 %)
Q2 2015	227.86	26.8 %	64.96	15.4 %	38.75	29.4 %
Q3 2015	210.78	18.8 %	50.78	26.5 %	27.13	47.3 %
Q4 2015	220.60	13.1 %	50.34	33.0 %	33.70	175.6 %
2015	878.67	19.7 %	220.20	24.2 %	128.69	38.9 %
Q1 2016	253.94	15.7 %	67.29	24.3 %	35.04	20.3 %
Q2 2016	259.77	14.0 %	84.30	29.8 %	61.24	58.0 %
Q3 2016	197.01	(6.5 %)	50.54	(0.5 %)	27.99	3.2 %
Q4 2016	189.94	(13.9 %)	4.86	(90.3 %)	(44.59)	(232.3 %)
2016	900.65	2.5 %	206.99	(6.0 %)	94.75	(26.4 %)
Q1 2017	202.44	(20.3 %)	41.19	(38.8 %)	14.04	(59.9 %)
Q2 2017	216.54	(16.6 %)	50.25	(40.4 %)	20.01	(67.3 %)
Q3 2017	208.34	5.8 %	46.97	(7.1 %)	26.33	(5.9 %)
Q4 2017	227.76	19.9 %	57.00	1072.0 %	29.59	166.4 %
2017	855.08	(5.1 %)	195.40	(5.6 %)	89.97	(5.1 %)
Q1 2018	206.67	2.1 %	51.73	25.6 %	28.41	102.4 %
Q2 2018	199.05	(8.1 %)	49.59	(1.3 %)	23.40	17.0 %
Q3 2018	176.40	(15.3 %)	33.17	(29.4 %)	13.16	(50.0 %)
Q4 2018	181.69	(20.2 %)	32.02	(43.8 %)	14.93	(49.6 %)
2018	763.80	(10.7 %)	166.51	(14.8 %)	79.90	(11.2 %)
Q1 2019	179.43	(13.2 %)	48.01	(7.2 %)	30.31	6.7 %
Q2 2019	169.94	(14.6 %)	38.26	(22.8 %)	15.56	(33.5 %)
Q3 2019	173.51	(1.6 %)	40.11	20.9 %	19.63	49.2 %
Q4 2019	185.52	2.1 %	39.27	22.6 %	22.88	53.3 %
2019	708.39	(7.3 %)	165.66	(0.5 %)	88.37	10.6 %
Q1 2020	195.02	8.7 %	52.22	8.8 %	36.28	19.7 %
Q2 2020	186.04	9.5 %	58.87	53.9 %	29.77	91.4 %
Q3 2020	213.31	22.9 %	51.06	27.3 %	22.70	15.6 %
Q4 2020	214.60	15.7 %	61.73	57.2 %	25.36	10.9 %
2020	808.95	14.2 %	223.88	35.1 %	114.11	29.1 %
Q1 2021	214.19	9.8 %	63.64	21.9 %	42.18	16.3 %
Q2 2021	202.49	8.8 %	57.77	(1.9 %)	37.59	26.3 %
Q3 2021	213.11	(0.1 %)	63.08	23.5 %	39.80	75.3 %

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
2011	458.28	7.5 %	121.33	16.9 %	95.18	15.9 %
2012	524.75	14.5 %	135.13	11.4 %	104.01	9.3 %
2013	586.28	11.7 %	130.06	(3.8 %)	91.55	(12.0 %)
2014	733.99	25.2 %	177.27	36.3 %	92.67	1.2 %
2015	878.67	19.7 %	220.20	24.2 %	128.69	38.9 %
2016	900.65	2.5 %	206.99	(6.0 %)	94.75	(26.4 %)
2017	855.08	(5.1 %)	195.40	(5.6 %)	89.97	(5.1 %)
2018	763.80	(10.7 %)	166.51	(14.8 %)	79.90	(11.2 %)
2019	708.39	(7.3 %)	165.66	(0.5 %)	88.37	10.6 %
2020	808.95	14.2 %	223.88	35.1 %	114.11	29.1 %

Profit Performance (Million)

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
Q1 2012	28.88	1.0 %	0.64	-	28.88	0.64
Q2 2012	29.59	3.3 %	0.66	-	29.59	0.66
Q3 2012	21.46	15.7 %	0.48	-	21.46	0.48
Q4 2012	25.03	32.0 %	0.56	-	25.03	0.56
2012	104.96	10.8 %	2.34	-	104.96	2.34
Q1 2013	31.12	7.8 %	0.69	-	31.12	0.69
Q2 2013	22.19	(25.0 %)	0.49	-	22.19	0.49
Q3 2013	18.80	(12.4 %)	0.42	-	18.80	0.42
Q4 2013	20.39	(18.6 %)	0.45	-	20.39	0.45
2013	92.50	(11.9 %)	2.06	-	92.50	2.06
Q1 2014	32.40	4.1 %	0.72	-	32.40	0.72
Q2 2014	31.06	40.0 %	0.69	-	31.06	0.69
Q3 2014	20.76	10.4 %	0.46	-	20.76	0.46
Q4 2014	10.28	(49.6 %)	0.23	-	10.28	0.23
2014	95.46	3.2 %	2.13	-	95.46	2.13
Q1 2015	27.72	(14.4 %)	0.62	-	27.72	0.62
Q2 2015	42.29	36.1 %	0.94	-	42.29	0.94
Q3 2015	25.47	22.7 %	0.57	-	25.47	0.57
Q4 2015	35.24	242.7 %	0.79	-	35.24	0.79
2015	130.72	36.9 %	2.91	-	130.72	2.91
Q1 2016	33.12	19.5 %	0.74	-	33.12	0.74
Q2 2016	59.29	40.2 %	1.32	-	59.29	1.32
Q3 2016	27.55	8.2 %	0.61	-	27.55	0.61
Q4 2016	(69.69)	(297.8 %)	(1.55)	(33.75)	(35.95)	(0.80)
2016	50.27	(61.5 %)	1.12	(33.75)	84.02	1.87
Q1 2017	15.54	(53.1 %)	0.35	-	15.54	0.35
Q2 2017	19.50	(67.1 %)	0.43	-	19.50	0.43
Q3 2017	27.00	(2.0 %)	0.60	-	27.00	0.60
Q4 2017	23.26	133.4 %	0.52	(1.24)	24.50	0.55
2017	85.30	69.7 %	1.90	(1.24)	86.54	1.93
Q1 2018	25.60	64.8 %	0.57	-	25.60	0.57
Q2 2018	20.26	3.9 %	0.45	-	20.26	0.45
Q3 2018	11.44	(57.6 %)	0.26	-	11.44	0.26
Q4 2018	4.87	(79.1 %)	0.11	-	4.87	0.11
2018	62.18	(27.1 %)	1.39	-	62.18	1.39
Q1 2019	29.99	17.1 %	0.67	-	29.99	0.67
Q2 2019	13.81	(31.8 %)	0.31	-	13.81	0.31
Q3 2019	16.64	45.4 %	0.37	-	16.64	0.37
Q4 2019	19.64	303.2 %	0.44	-	19.64	0.44
2019	80.09	28.8 %	1.79	-	80.09	1.79
Q1 2020	33.17	10.6 %	0.74	-	33.17	0.74
Q2 2020	25.78	86.6 %	0.57	-	25.78	0.57
Q3 2020	16.32	(1.9 %)	0.36	-	16.32	0.36
Q4 2020	22.00	12.0 %	0.49	-	22.00	0.49
2020	97.27	21.4 %	2.17	-	97.27	2.17
Q1 2021	35.73	7.7 %	0.80	-	35.73	0.80
Q2 2021	30.74	19.2 %	0.69	-	30.74	0.69
Q3 2021	33.17	103.2 %	0.74	-	33.17	0.74

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
2011	94.72	11.8 %	2.11	-	94.72	2.11
2012	104.96	10.8 %	2.34	-	104.96	2.34
2013	92.50	(11.9 %)	2.06	-	92.50	2.06
2014	95.46	3.2 %	2.13	-	95.46	2.13
2015	130.72	36.9 %	2.91	-	130.72	2.91
2016	50.27	(61.5 %)	1.12	(33.75)	84.02	1.87
2017	85.30	69.7 %	1.90	(1.24)	86.54	1.93
2018	62.18	(27.1 %)	1.39	-	62.18	1.39
2019	80.09	28.8 %	1.79	-	80.09	1.79
2020	97.27	21.4 %	2.17	-	97.27	2.17

Profitability

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2012	25.88 %	25.84 %	20.09 %
Q2 2012	25.57 %	25.38 %	19.54 %
Q3 2012	25.99 %	25.46 %	19.56 %
Q4 2012	25.75 %	25.14 %	20.00 %
2012	25.75 %	25.14 %	20.00 %
Q1 2013	25.56 %	24.89 %	19.81 %
Q2 2013	24.27 %	23.17 %	18.27 %
Q3 2013	22.61 %	21.99 %	17.36 %
Q4 2013	21.86 %	20.98 %	15.78 %
2013	22.18 %	20.98 %	15.78 %
Q1 2014	21.26 %	20.31 %	15.06 %
Q2 2014	23.76 %	21.17 %	15.55 %
Q3 2014	24.60 %	20.97 %	14.88 %
Q4 2014	24.15 %	19.46 %	12.88 %
2014	24.15 %	19.59 %	13.01 %
Q1 2015	24.42 %	18.66 %	11.64 %
Q2 2015	24.04 %	18.90 %	12.33 %
Q3 2015	24.35 %	19.23 %	12.40 %
Q4 2015	25.06 %	21.32 %	14.88 %
2015	25.06 %	21.32 %	14.88 %
Q1 2016	25.56 %	21.44 %	14.91 %
Q2 2016	26.74 %	23.27 %	16.20 %
Q3 2016	27.11 %	23.91 %	16.67 %
Q4 2016	22.98 %	16.07 %	9.33 %
2016	22.98 %	17.75 %	9.33 %
Q1 2017	21.30 %	14.58 %	7.82 %
Q2 2017	18.22 %	10.27 %	3.31 %
Q3 2017	17.53 %	9.96 %	3.19 %
Q4 2017	22.85 %	18.52 %	10.12 %
2017	22.85 %	18.52 %	10.12 %
Q1 2018	23.97 %	20.17 %	11.24 %
Q2 2018	24.39 %	20.91 %	11.57 %
Q3 2018	23.64 %	20.41 %	10.10 %
Q4 2018	21.80 %	20.00 %	8.14 %
2018	21.80 %	20.00 %	8.14 %
Q1 2019	22.10 %	21.08 %	9.04 %
Q2 2019	21.41 %	21.09 %	8.50 %
Q3 2019	22.48 %	21.77 %	9.27 %
Q4 2019	23.38 %	22.17 %	11.31 %
2019	23.38 %	22.17 %	11.31 %
Q1 2020	23.46 %	22.32 %	11.50 %
Q2 2020	25.74 %	23.29 %	12.87 %
Q3 2020	25.83 %	22.00 %	12.17 %
Q4 2020	27.68 %	21.05 %	12.02 %
2020	27.68 %	21.05 %	12.02 %
Q1 2021	28.41 %	20.86 %	12.06 %
Q2 2021	27.73 %	21.19 %	12.41 %
Q3 2021	29.16 %	23.15 %	14.41 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
2011	26.48 %	26.56 %	20.67 %
2012	25.75 %	25.14 %	20.00 %
2013	22.18 %	20.98 %	15.78 %
2014	24.15 %	19.59 %	13.01 %
2015	25.06 %	21.32 %	14.88 %
2016	22.98 %	17.75 %	9.33 %
2017	22.85 %	18.52 %	10.12 %
2018	21.80 %	20.00 %	8.14 %
2019	23.38 %	22.17 %	11.31 %
2020	27.68 %	21.05 %	12.02 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2012	27.57 %	27.57 %	22.41 %
Q2 2012	27.39 %	27.12 %	21.56 %
Q3 2012	24.85 %	23.55 %	17.74 %
Q4 2012	23.20 %	22.29 %	18.19 %
Q1 2013	26.65 %	26.37 %	21.41 %
Q2 2013	22.35 %	20.42 %	15.60 %
Q3 2013	17.89 %	18.61 %	13.97 %
Q4 2013	20.43 %	18.63 %	12.42 %
Q1 2014	23.64 %	22.99 %	17.82 %
Q2 2014	31.31 %	23.55 %	17.28 %
Q3 2014	22.63 %	18.45 %	11.70 %
Q4 2014	19.41 %	13.33 %	5.27 %
Q1 2015	24.67 %	19.55 %	12.63 %
Q2 2015	28.51 %	23.38 %	18.56 %
Q3 2015	24.09 %	19.85 %	12.09 %
Q4 2015	22.82 %	22.37 %	15.97 %
Q1 2016	26.50 %	20.19 %	13.04 %
Q2 2016	32.45 %	29.83 %	22.83 %
Q3 2016	25.65 %	22.64 %	13.99 %
Q4 2016	2.56 %	(15.05 %)	(18.93 %)
Q1 2017	20.35 %	15.00 %	7.68 %
Q2 2017	23.20 %	16.81 %	9.01 %
Q3 2017	22.54 %	20.74 %	12.96 %
Q4 2017	25.02 %	21.25 %	10.76 %
Q1 2018	25.03 %	21.90 %	12.39 %
Q2 2018	24.91 %	19.67 %	10.18 %
Q3 2018	18.81 %	18.43 %	6.49 %
Q4 2018	17.62 %	19.73 %	2.68 %
Q1 2019	26.76 %	26.61 %	16.71 %
Q2 2019	22.51 %	19.46 %	8.13 %
Q3 2019	23.12 %	21.16 %	9.59 %
Q4 2019	21.17 %	21.29 %	10.59 %
Q1 2020	26.78 %	26.82 %	17.01 %
Q2 2020	31.64 %	23.57 %	13.86 %
Q3 2020	23.94 %	16.85 %	7.65 %
Q4 2020	28.77 %	17.82 %	10.25 %
Q1 2021	29.71 %	25.54 %	16.68 %
Q2 2021	28.53 %	24.72 %	15.18 %
Q3 2021	29.60 %	24.62 %	15.57 %

Per Share Data (Riyal)

Compared With The

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
Q1 2012	44.85	2.12	2.12	12.97
Q2 2012	44.85	2.14	2.14	12.57
Q3 2012	44.85	2.20	2.20	13.04
Q4 2012	44.85	2.34	2.34	13.60
Q1 2013	44.85	2.39	2.39	18.19
Q2 2013	44.85	2.23	2.23	17.24
Q3 2013	44.85	2.17	2.17	17.65
Q4 2013	44.85	2.06	2.06	18.11
Q1 2014	44.85	2.09	2.09	17.28
Q2 2014	44.85	2.29	2.29	17.97
Q3 2014	44.85	2.33	2.33	18.46
Q4 2014	44.85	2.11	2.11	18.69
Q1 2015	44.85	2.00	2.00	19.26
Q2 2015	44.85	2.25	2.25	18.66
Q3 2015	44.85	2.36	2.36	19.22
Q4 2015	44.85	2.91	2.91	20.01
Q1 2016	44.85	3.03	3.03	20.60
Q2 2016	44.85	3.41	3.41	21.16
Q3 2016	44.85	3.46	3.46	21.75
Q4 2016	44.85	1.12	1.87	20.18
Q1 2017	44.85	0.73	1.48	20.51
Q2 2017	44.85	(0.16)	0.59	20.93
Q3 2017	44.85	(0.17)	0.58	21.52
Q4 2017	44.85	1.90	1.93	21.98
Q1 2018	44.85	2.13	2.15	22.38
Q2 2018	44.85	2.14	2.17	21.83
Q3 2018	44.85	1.80	1.82	22.09
Q4 2018	44.85	1.39	1.39	22.23
Q1 2019	44.85	1.48	1.48	22.90
Q2 2019	44.85	1.34	1.34	22.20
Q3 2019	44.85	1.46	1.46	22.57
Q4 2019	44.85	1.79	1.79	23.03
Q1 2020	44.85	1.86	1.86	23.77
Q2 2020	44.85	2.12	2.12	22.34
Q3 2020	44.85	2.12	2.12	22.71
Q4 2020	44.85	2.17	2.17	23.12
Q1 2021	44.85	2.23	2.23	23.92
Q2 2021	44.85	2.34	2.34	23.60
Q3 2021	44.85	2.71	2.71	24.34

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
2011	44.85	2.11	2.11	12.32
2012	44.85	2.34	2.34	13.60
2013	44.85	2.06	2.06	18.11
2014	44.85	2.13	2.13	18.69
2015	44.85	2.91	2.91	20.01
2016	44.85	1.12	1.87	20.18
2017	44.85	1.90	1.93	21.98
2018	44.85	1.39	1.39	22.23
2019	44.85	1.79	1.79	23.03
2020	44.85	2.17	2.17	23.12

Multiple Ratios (End of Period Price)

Compared With The

Period	P/E	Adjusted P/E	Price/book
Q1 2012	-	-	-
Q2 2012	-	-	-
Q3 2012	-	-	-
Q4 2012	-	-	-
Q1 2013	30.02	30.02	3.94
Q2 2013	26.07	26.07	3.37
Q3 2013	25.16	25.16	3.09
Q4 2013	26.43	26.43	3.01
Q1 2014	29.41	29.41	3.56
Q2 2014	32.48	32.48	4.14
Q3 2014	32.55	32.55	4.11
Q4 2014	26.03	26.03	2.94
Q1 2015	30.88	30.88	3.21
Q2 2015	28.44	28.44	3.44
Q3 2015	22.37	22.37	2.74
Q4 2015	19.04	19.04	2.77
Q1 2016	16.69	16.69	2.46
Q2 2016	18.71	18.71	3.02
Q3 2016	15.98	15.98	2.54
Q4 2016	58.81	35.19	3.27
Q1 2017	73.26	36.05	2.60
Q2 2017	NEG	79.11	2.25
Q3 2017	NEG	69.35	1.87
Q4 2017	22.90	22.57	1.98
Q1 2018	26.45	26.11	2.51
Q2 2018	27.67	27.32	2.72
Q3 2018	25.44	25.05	2.07
Q4 2018	36.28	36.28	2.26
Q1 2019	31.56	31.56	2.05
Q2 2019	43.34	43.34	2.62
Q3 2019	37.22	37.22	2.40
Q4 2019	27.22	27.22	2.11
Q1 2020	19.53	19.53	1.53
Q2 2020	19.83	19.83	1.88
Q3 2020	26.08	26.08	2.43
Q4 2020	24.62	24.62	2.31
Q1 2021	24.08	24.08	2.24
Q2 2021	29.10	29.10	2.88
Q3 2021	23.12	23.12	2.58

Period	P/E	Adjusted P/E	Price/book
2011	-	-	-
2012	-	-	-
2013	26.43	26.43	3.01
2014	25.77	25.77	2.94
2015	19.04	19.04	2.77
2016	58.81	35.19	3.27
2017	22.90	22.57	1.98
2018	36.28	36.28	2.26
2019	27.22	27.22	2.11
2020	24.62	24.62	2.31

Business Segments (Million)

Compared With The

Period	Medical Services	Pharmacies
Q1 2012	102.83	26.04
Q2 2012	109.44	27.83
Q3 2012	96.87	24.14
Q4 2012	109.84	27.76
Q1 2013	117.72	27.65
Q2 2013	115.21	26.98
Q3 2013	109.28	25.28
Q4 2013	134.04	30.12
Q1 2014	149.16	32.67
Q2 2014	149.31	30.43
Q3 2014	149.57	27.87
Q4 2014	161.93	33.06
Q1 2015	184.80	34.63
Q2 2015	196.41	31.45
Q3 2015	180.37	30.41
Q4 2015	191.80	28.80
Q1 2016	220.78	33.16
Q2 2016	230.14	29.62
Q3 2016	173.08	23.93
Q4 2016	162.66	27.28
Q1 2017	176.04	26.40
Q2 2017	190.13	26.41
Q3 2017	185.07	23.27
Q4 2017	202.08	25.76
Q1 2018	183.47	23.20
Q2 2018	175.85	23.20
Q3 2018	155.67	20.74
Q4 2018	154.94	26.74
Q1 2019	157.71	21.72
Q2 2019	149.87	20.07
Q3 2019	153.76	19.76
Q4 2019	162.79	22.72
Q1 2020	170.81	24.20
Q2 2020	164.47	21.52
Q3 2020	187.44	25.56
Q4 2020	192.76	22.19
Q1 2021	188.50	25.70
Q2 2021	178.18	24.30
Q3 2021	187.54	25.57

Period	Medical Services	Pharmacies
2011	361.34	96.95
2012	418.98	105.76
2013	476.25	110.02
2014	609.97	124.03
2015	753.38	125.28
2016	786.66	113.99
2017	753.32	101.85
2018	669.93	93.87
2019	624.13	84.27
2020	715.48	93.47

Analysts Estimates (Million)

Item	Q3 2021 (e)	Q3 2021 (a)	Change‬
Average	30.85	33.17	7.53 %

Estimates vs Actual (Million)

Item	Q3 2021 (e)	Q3 2021 (a)	Change
AlJazira Capital	31.70	33.17	4.6 %
Al Rajhi Capital	30.00	33.17	10.6 %

Twitter

Facebook

Linked in

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Care net profit up 32% to SAR 99.6 mln in 9M 2021

Financials (M)

Current Quarter Comparison (M)

View other reports

Share Price

National Medical Care Co. (CARE)

Financial Ratios

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million)

Revenue by Business Segment (Latest) 2021 Q3

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Popular Links

Quick Links

About Us

Join Us

Follow Us

Care net profit up 32% to SAR 99.6 mln in 9M 2021

Financials (M)

Current Quarter Comparison (M)

View other reports

Share Price

National Medical Care Co. (CARE)

Financial Ratios

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million) Q3 2021

Revenue by Business Segment (Latest) 2021 Q3

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Popular Links

Quick Links

About Us

Join Us

Follow Us

Business Segments (Million)